Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Safety and Efficacy of Belatacept, Antithymocyte Globulin, and Sirolimus in Recipients of Non-HLA-identical Living-donor Renal Transplants (ITN023ST)

Next Previous
X
Search
Trial Profile

The Safety and Efficacy of Belatacept, Antithymocyte Globulin, and Sirolimus in Recipients of Non-HLA-identical Living-donor Renal Transplants (ITN023ST)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belatacept (Primary) ; Antithymocyte globulin; Daclizumab; Methylprednisolone; Sirolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms BESTT

    • Most Recent Events

    • 04 Nov 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top